Partnership Opportunities
2023 Partners
ALS Pharma and Biotech Drug Developers Seek:
In vivomodels of neurodegeneration to study ALS pathophysiology and behavior
In vitromodels and cell-based assays, such as iPSCs, patient-derived motor neurons, and organoid models
Novel biomarker technology, from CSF and blood to digital biomarkers to detect motor neurone degeneration and monitor disease progression
Wearable technology to facilitate sensitive, remote patient data collection
Early-stage patients to test efficacy in promising emerging ALS candidates
Genetic sequencing companies to study pathophysiology and aid target identification for novel ALS candidates
The 2nd ALS Drug Development Summit will allow your company to:
Network with biopharma key opinion leaders and decision-makers at the forefront of ALS drug development to forge new business opportunities
Secure your company as an innovative field leader by presenting your product or service to an engaged audience of discovery, preclinical and clinical ALS expert
Meet neuroscience companies currently in translational development, yet to select long-term commercial partners